Business Monitor International


Malaysia Pharmaceuticals & Healthcare Report

Published 14 July 2014

  • 139 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Malaysia Pharmaceuticals & Healthcare Report

BMI View: The Malaysian pharmaceutical and healthcare markets are set to grow significantly. Promising long-term economic growth, local government support, an   ageing population and a   surge of chronic non-communicable diseases , sector growth will continue to be driven . However, a slowdown in economic growth in 2014, coupled with the fact that investment in the pharmaceuticals sector will take longer than expected to bring returns, present downside risks to our outlook.

Headline Expenditure Projections

  • Pharmaceuticals: MYR6.60bn (USD2.10bn) in 2013 to MYR7.51bn (USD2.35bn) in 2014; +13.7% in local currency and +12.0% in US dollar terms. Forecast increased from Q314 to better suit current market conditions.

  • Healthcare: MYR40.27bn (USD12.78bn) in 2013 to MYR43.79bn (USD13.68bn) in 2014; +8.8% in local currency and +7.1% in US dollar terms. Forecast in line with last quarter's figures.

Risk/Reward Rating: In Q414, Malaysia's Pharmaceutical Risk/Reward Rating (RRR) stood at 60, marking no change since Q114. It posts above-average scores for every indicator in the Asia Pacific region, and ranks eighth out of the 19 key markets. 

Key Trends And Developments

August

In response to allegations that the MYR86mn (USD27.1mn) Halal hub project in Kiansam in Labuan, East Malaysia, was a mistake, former Labuan Member of Parliament Datuk Suhaili Abdul Rahman has stated that his successors are responsible for the failure of the project. 'The Halal hub was not born as a white elephant project but turned into one due to those responsible having strayed from the goal of using the hub for producing high-quality halal products,' said Suhaili (reports the Daily Express). The hub, which was initiated in 2009, aimed to add value to Labuan's marine products and cater for potential demand from the ASEAN and Gulf States. The project's plan also included processing of pharmaceuticals, herbs and cosmetics.

Malaysia, with a Muslim population of around 60%, aims to attract...

Table of Contents

BMI Industry View
7
SWOT
9
Political
11
Economic
13
Business Environment
15
Industry Forecast
17
Pharmaceutical Market Forecast
17
Table: Pharmaceutical Sales, Historical Data And Forecasts (Malaysia 2010-2018)
19
Healthcare Market Forecast
20
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Malaysia 2010-2018)
21
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Malaysia 2010-2018)
22
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Malaysia 2010-2018)
22
Prescription Drug Market Forecast
23
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Malaysia 2010-2018)
24
Patented Drug Market Forecast
25
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Malaysia 2010-2018)
26
Generic Drug Market Forecast
27
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Malaysia 2010-2018)
28
OTC Medicine Market Forecast
29
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Malaysia 2010-2018)
30
Pharmaceutical Trade Forecast
31
Table: Pharmaceutical Trade Data And Forecasts (Malaysia 2012-2018)
33
Table: Pharmaceutical Trade Data And Forecasts local currency (Malaysia 2012-2018)
34
Other Healthcare Data
35
Key Risks To BMI's Forecast Scenario
36
Macroeconomic Forecasts
38
Economic Analysis
38
Table: Malaysia - Economic Activity
44
Industry Risk Reward Ratings
45
Asia Risk/Reward Ratings
45
Malaysia Risk/Reward Ratings
51
Rewards
51
Risks
52
Market Overview
53
Industry Trends And Developments
55
Epidemiology
55
Healthcare Sector
59
Table: 2011 Entry Points Projects Summary
61
Healthcare Insurance
62
Table: Main Features Of 1Care
62
Healthcare Funding
64
Healthcare Sector Developments
65
Table: Public Sector And Private Sector Healthcare Developments
65
Medical Tourism
66
Research & Development
68
Clinical Trials
70
Regulatory Development
73
Regulatory Regime
73
Table: Drug Applications by Type, 2002-2010
75
Table: Registered Pharmaceutical Products by Type, 2002-10
75
Regulatory Developments
76
Intellectual Property Issues
80
Pricing Regime
85
Competitive Landscape
87
Domestic Industry
87
Foreign Industry
89
Table: Leading Malaysian Pharmaceutical And Healthcare Companies
91
Culture-Specific Medicines
92
Pharmaceutical Distribution
95
Table: Drug Wholesalers & Importers, 2002-2010
95
Pharmaceutical Retail Sector
95
Company Profile
98
Bumimedic
98
Kotra Pharma
100
Pfizer
103
Pharmaniaga
106
Prime Pharmaceutical
110
Hovid
112
Chemical Company Of Malaysia
116
GlaxoSmithKline
119
Novartis
123
Merck & Co
126
Sanofi
129
Eli Lilly Malaysia
131
Ranbaxy Malaysia
133
Demographic Forecast
135
Table: Malaysia's Population By Age Group, 1990-2020 ('000)
136
Table: Malaysia's Population By Age Group, 1990-2020 (% of total)
137
Table: Malaysia's Key Population Ratios, 1990-2020
138
Table: Malaysia's Rural And Urban Population, 1990-2020
138
Glossary
139
Methodology
141
Pharmaceutical Expenditure Forecast Model
141
Healthcare Expenditure Forecast Model
141
Notes On Methodology
142
Risk/Reward Ratings Methodology
143
Ratings Overview
144
Table: Pharmaceutical Risk/Reward Ratings Indicators
144
Indicator Weightings
145

The Malaysia Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Malaysia Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Malaysian pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Malaysia to test other views - a key input for successful budgeting and strategic business planning in the Malaysian pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Malaysian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Malaysia.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc